Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

NCT00154375 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma Multiforme
Astrocytoma

Interventions

DRUG: Imatinib mesylate
DRUG: Hydroxyurea

Sponsor

Novartis Pharmaceuticals